Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy - ScienceDirect
Did You Know – IMFINZI® (durvalumab) for unresectable Stage 3 NSCLC
Endocrinopathies from checkpoint inhibitors: Incidence, outcomes, and management | Cleveland Clinic Journal of Medicine
Immune-checkpoint inhibitors: long-term implications of toxicity | Nature Reviews Clinical Oncology
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response - BJMO
Full article: Patient-Reported Outcomes with Durvalumab by PD-L1 Expression and Prior Chemoradiotherapy-Related Variables in Unresectable Stage III Non-Small-Cell Lung Cancer
Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer | ONS
My Long-Term Side Effects of Chemo | Lymphoma News Today
Treatment patterns and long‐term survival outcomes for patients with stage III non‐small cell lung cancer: A retrospective study - Kumari - Asia-Pacific Journal of Clinical Oncology - Wiley Online Library
Durvalumab (Imfinzi) Drug Information
Immunotherapy: Pushing the Frontier of Cancer Medicine | AACR Cancer Progress Report
Side-effects of Short Term and Long Term Glucocortcoid Use | Download Table
Long-Term Side Effects of Immune Checkpoint Inhibitors - NCI
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy - ScienceDirect
Frontiers | Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
GeparNUEVO: durvalumab plus neoadjuvant chemotherapy in TNBC demonstrates long-term clinical benefit - Onco Americas
Durvalumab (Imfinzi) Drug Information
Frontiers | What Is Long-Term Survival and Which First-Line Immunotherapy Brings Long-Term Survival for Advanced Wild-Type Non-Small Cell Lung Cancer: A Network Meta-Analysis Based on Integrated Analysis
The ocular side effects of emerging oncology meds
Immune-checkpoint inhibitors: long-term implications of toxicity | Nature Reviews Clinical Oncology
PDF) Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer.
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial | Nature Medicine
Immune Checkpoint Inhibitor Side Effects & Toxicity More Common Than Reported - CancerConnect
Does immunotherapy have side effects? | MD Anderson Cancer Center
Long-Term Side Effects of Immune Checkpoint Inhibitors - NCI
